1. Dyne Therapeutics raised approximately $402.5 million in a stock offering. 2. Offering included 21.8 million shares at $18.44 each. 3. Proceeds will support development in neuromuscular disease therapeutics. 4. The offering was managed by top investment banks. 5. Dyne is advancing clinical programs for significant muscle diseases.
FAQ
Why Bullish?
The substantial capital influx provides financial stability and growth potential. Historical precedents show shares typically respond positively to successful offerings for R&D.
How important is it?
The fundraising indicates strong market confidence, while supporting cash flow for R&D. Potential growth in the neuromuscular disease market enhances the company’s future outlook.
Why Short Term?
Stock offerings often lead to immediate market reactions. Previous similar offerings have shown short-term bullish price movements due to increased cash reserves.
Dyne Therapeutics Closes Upsized Public Offering, Generating $402.5 Million
Waltham, Mass., December 11, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a leading clinical-stage company, has successfully closed its upsized underwritten public offering, raising approximately $402.5 million.
Details of the Public Offering
Dyne Therapeutics announced the closing of its previously reported offering of 21,827,549 shares of common stock at a public offering price of $18.44 per share. This amount includes 2,847,071 shares that were issued upon the full exercise of the underwriters’ option to purchase additional shares.
All shares issued in this offering were sold by Dyne. The company engaged Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities as joint book-running managers for this successful capital raise.
Financial Impact and Use of Proceeds
The gross proceeds from this offering are approximately $402.5 million before the deduction of underwriting discounts, commissions, and offering expenses. Such substantial funding will support Dyne's mission to deliver innovative therapies targeting genetically driven neuromuscular diseases.
Regulatory Compliance and Offering Terms
The public offering was conducted under a shelf registration statement on Form S-3, which was filed with the Securities and Exchange Commission (SEC) on March 5, 2024. This statement became automatically effective upon filing.
A final prospectus supplement providing details on the offering has been filed with the SEC and can be accessed at www.sec.gov. Interested parties can also request copies of the final prospectus from the following:
- Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, Email: prospectus@morganstanley.com
- Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, Telephone: (877) 821-7388, Email: Prospectus_Department@Jefferies.com
- Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Telephone: (415) 364-2720, Email: syndprospectus@stifel.com
- Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, Telephone: (212) 518-9544, Email: GSEquityProspectusDelivery@guggenheimpartners.com
This announcement is not an offer to sell or a solicitation of an offer to buy these securities.
About Dyne Therapeutics
Dyne Therapeutics is dedicated to improving the lives of individuals affected by genetically driven neuromuscular disorders. The company is actively developing therapeutics that target both muscle and the central nervous system (CNS), focusing on diseases such as myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), among others.